Grundinformationen
- Standard-SMILES
C[C@@H](O)CCCCn1c(=O)c2c(ncn2C)n(C)c1=O- InChIKey
NSMXQKNUPPXBRG-SECBINFHSA-N- Summenformel
- C13H20N4O3
- Durchschnittliche Molmasse
- 280,32 g/mol
- Monoisotopische Masse
- 280,1535405
Überblick
(R)-lisofylline is a 1-(5-hydroxyhexyl)-3,7-dimethyl-3,7-dihydro-1H-purine-2,6-dione that has (R)-configuration. A synthetic small molecule which was under development for the treatment of type 1 diabetes mellitus. It has a role as an immunomodulator and an anti-inflammatory agent. It is an enantiomer of a (S)-lisofylline.
Namen und Bezeichner
- Bevorzugter Name
- Lisofylline
- IUPAC
- 1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dione
Namen und Synonyme
(R)-LisofyllineLISOFYLLINE100324-81-0ProTecLisophyllineCT-1501RlisofilinaCT 1501R1-[(5R)-5-hydroxyhexyl]-3,7-dimethylpurine-2,6-dioneLisofylline, (r)-lisofyllinumCT1501R
Weitere Namen anzeigen
(R)-Lisophylline1-[(R)-5-hydroxyhexyl]theobromineDTXSID7058709CHEBI:143527L1F2Q2X9561-((R)-5-Hydroxyhexyl)theobromine1-(5R-Hydroxyhexyl)-3,7-dimethylxanthine1-[(5R)-5-hydroxyhexyl]-3,7-dimethyl-2,3,6,7-tetrahydro-1H-purine-2,6-dione
Datenbank-Bezeichner
- CAS
100324-81-0- PubChem CID
- 501254
- DTXSID
DTXSID7058709- ChEMBL
CHEMBL1411- ChEBI
CHEBI:143527- UNII
- L1F2Q2X956
- Nikkaji
- J731.039K
Eigenschaften
Berechnete Struktureigenschaften
- XLogP
- 0,7
- Polarare Oberfläche (TPSA)
- 78,7 Ų
- H-Brücken-Donoren
- 1
- H-Brücken-Akzeptoren
- 4
- Frei drehbare Bindungen
- 5
- Schwere Atome
- 20
- Formalladung
- 0
- Komplexität
- 390
Experimentelle und physikochemische Eigenschaften
Drugs
Pharmaceuticals -> Metabolite of Pentoxifylline
Pharmaceuticals -> Listed in ZINC15
Chemie und Industrie
Pharmakologische Informationen
Metabolism/MetabolitesLisofylline has known human metabolites that include lisofylline 4,5-diol and pentoxifylline.
MeSH Pharmacological Classification
Substances that augment, stimulate, activate, potentiate, or modulate the immune response at either the cellular or humoral level. The classical agents (Freund's adjuvant, BCG, Corynebacterium parvum, et al.) contain bacterial antigens. Some are endogenous (e.g., histamine, interferon, transfer factor, tuftsin, interleukin-1). Their mode of action is either non-specific, resulting in increased immune responsiveness to a wide variety of antigens, or antigen-specific, i.e., affecting a restricted type of immune response to a narrow group of antigens. The therapeutic efficacy of many biological response modifiers is related to their antigen-specific immunoadjuvanticity.
Anti-inflammatory agents that are non-steroidal in nature. In addition to anti-inflammatory actions, they have analgesic, antipyretic, and platelet-inhibitory actions. They act by blocking the synthesis of prostaglandins by inhibiting cyclooxygenase, which converts arachidonic acid to cyclic endoperoxides, precursors of prostaglandins. Inhibition of prostaglandin synthesis accounts for their analgesic, antipyretic, and platelet-inhibitory actions; other mechanisms may contribute to their anti-inflammatory effects.
Agents that suppress immune function by one of several mechanisms of action. Classical cytotoxic immunosuppressants act by inhibiting DNA synthesis. Others may act through activation of T-CELLS or by inhibiting the activation of HELPER CELLS. While immunosuppression has been brought about in the past primarily to prevent rejection of transplanted organs, new applications involving mediation of the effects of INTERLEUKINS and other CYTOKINES are emerging.
Drugs used to potentiate the effectiveness of radiation therapy in destroying unwanted cells.
Zugehörige Reaktionen
2
Verknüpfte Notizen
Wird geladen…